Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial
Abstract Background Despite robust weight loss and cardiometabolic benefit, lean mass loss following sleeve gastrectomy (SG) confers health risk. Bisphosphonates are a potential therapeutic agent for lean mass maintenance. Thus, our objective was to explore the effect of 6 months of risedronate (vs....
Uloženo v:
Hlavní autoři: | , , , , , , , , |
---|---|
Médium: | Kniha |
Vydáno: |
Wiley,
2023-01-01T00:00:00Z.
|
Témata: | |
On-line přístup: | Connect to this object online. |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Jednotka 1 | Dostupné |